Evidence map›Paper›PMID 37692165›Full record

ArticleFrontiers in cellular and infection microbiology2023

Gut microbiota dysbiosis characterized by abnormal elevation of

Xiuping Liang, Yanhong Li, Lu Cheng, Yinlan Wu, Tong Wu, Ji Wen, Deying Huang, Zehui Liao, Chunyu Tan, Yubin Luo and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. The lung microbiome in interstitial lung disease.Breathe (Sheffield, England) · 2025
    Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiuping LiangDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Yanhong LiDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Lu ChengDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Yinlan WuDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Tong WuDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Ji WenDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Deying HuangDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Zehui LiaoDepartment of Rheumatolopy and Immunolopy, Meishan People's Hospital, Meishan, Sichuan, China.
Chunyu TanDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Yubin LuoDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Yi LiuDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Sichuan University · CNWest China Hospital of Sichuan University · CNMeizhou City People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: The gut microbiota plays an important role in human health. In this study, we aimed to investigate whether and how gut microbiota communities are altered in patients with immune-mediated necrotizing myopathy (IMNM) and provide new ideas to further explore the pathogenesis of IMNM or screen for its clinical therapeutic targets in the future. Methods: The gut microbiota collected from 19 IMNM patients and 23 healthy controls (HCs) were examined by using 16S rRNA gene sequencing. Alpha and beta-diversity analyses were applied to examine the bacterial diversity and community structure. Welch's t test was performed to identify the significantly abundant taxa of bacteria between the two groups. Spearman correlation analysis was performed to analyze the correlation between gut microbiota and clinical indicators. A receiver operator characteristic (ROC) curve was used to reflect the sensitivity and specificity of microbial biomarker prediction of IMNM disease. P < 0.05 was considered statistically significant. Results: Nineteen IMNM patients and 23 HCs were included in the analysis. Among IMNM patients, 94.74% (18/19) of them used glucocorticoids, while 57.89% (11/19) of them used disease-modifying antirheumatic drugs (DMARDs), and the disease was accessed by MITAX (18.26 ± 8.62) and MYOACT (20.68 ± 8.65) scores. Participants in the groups were matched for gender and age. The diversity of the gut microbiota of IMNM patients differed and decreased compared to that of HCs (Chao1, Shannon, and Simpson indexes: p < 0.05). In IMNM patients, the relative abundances of Bacteroides, Roseburia, and Coprococcus were decreased, while that of Lactobacillus and Streptococcus were relatively increased. Furthermore, in IMNM patients, Lactobacillus was positively correlated with the levels of anti-signal recognition particle (SRP) antibodies, anti-Ro52 antibodies, and erythrocyte sedimentation rate (ESR), while Streptococcus was positively correlated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies and C-reactive protein (CRP). Roseburia was negatively correlated with myoglobin (MYO), cardiac troponin T (cTnT), ESR, CRP, and the occurrence of interstitial lung disease (ILD). Bacteroides was negatively correlated with ESR and CRP, and Coprococcus was negatively correlated with ESR. Finally, the prediction model was built using the top five differential genera, which was verified using a ROC curve (area under the curve (AUC): 87%, 95% confidence interval: 73%-100%). Conclusion: We observed a characteristic compositional change in the gut microbiota with an abnormal elevation of Lactobacillus in IMNM patients, which was accompanied by changes in clinical indicators. This suggests that gut microbiota dysbiosis occurs in IMNM patients and is correlated with systemic autoimmune features.

Indexed as

Autoimmune DiseasesDysbiosisGastrointestinal MicrobiomeLactobacillusMyositisFemaleHumansMaleMiddle AgedNecrosisclinical indicatorsdysbiosisgut microbiotaimmune-mediated necrotizing myopathylactobacillus

Identifiers

PMID37692165
PMCPMC10486907
OpenAlexW4386156362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.